Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Par Pacific upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Par Pacific (PARR) to Overweight from Neutral with a price target of $25, up from $23. The company’s non-refining businesses “provide underappreciated downside support in current low margin environment,
ResMed initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed
Piper Sandler Upgrades NIKE (NKE)
Fintel reports that on January 10, 2025, Piper Sandler upgraded their outlook for NIKE (NYSE:NKE) from Neutral to Overweight. Analyst Price Forecast Suggests 25.85% Upside As of December 23, 2024, the average one-year price target for NIKE is $89.
4h
Arhaus price target raised to $15 from $14 at Piper Sandler
Piper Sandler raised the firm’s price target on Arhaus (ARHS) to $15 from $14 and keeps an Overweight rating on the shares ...
21h
on MSN
Valero and Par Pacific upgraded, Phillips 66 cut at Piper Sandler in shift of refiner ratings
Valero Energy (NYSE:VLO) +1.4% and Par Pacific (PARR) +3% in Friday's trading as Piper Sandler upgrades both stocks to ...
1d
Nike upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler analyst Anna Andreeva upgraded Nike (NKE) to Overweight from Neutral with a price target of $90, up from $72. The firm says that ...
5d
Kenvue stock still has 'ample room': Piper Sandler
Despite recent share appreciation, Piper Sandler believes there is still significant upside for Kenvue. “Though shares have ...
4d
on MSN
Coca-Cola and PepsiCo land bull ratings at Piper Sandler
Piper Sandler dipped into the beverage sector on Tuesday by issuing new Overweight ratings on Coca-Cola (NYSE:KO) and PepsiCo ...
Nasdaq
1mon
Poseida Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Piper
Sandler
downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight with an unchanged price target of $10 following Roche’s announced acquisition for $9 per share in cash and $4 per ...
6h
1 Magnificent Dividend Growth Stock That Could Soar 20% in 2025, According to a Couple of Wall Street Analysts
On Monday, Jan. 7, Michael Lavery at Piper Sandler initiated coverage of the beverage giant, with an overweight rating and a ...
4d
Piper Sandler: Mid-Market But Better Indexed To Lax FTC (Rating Upgrade)
Piper Sandler Companies is gaining traction with a recovering market. Find out why PIPR stock is becoming an attractive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Trade
New York Stock Exchange
Bath & Body Works
Coca-Cola
PepsiCo
Feedback